Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to ...

GlobalData analysis suggests that China will lead with the highest number of prevalent cases of Alzheimer’s disease in 2033.

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.

Coave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.

A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).